Company Overview. Founded in 1983 and incorporated in 1988. • The firm has grown from two employees to a staff of over 40 full time associates in multiple states. Average tenure with the company is 7 years and employee turnover is less than 10%. • HydroCorp Conducts over 25,000 on site, Cross-Connection Control Inspections annually. • HydroCorp provided Cross-Connection Control Program Management Services to over 240 communities in several states including: Michigan, Wisconsin, Delaware, Maryland, Virginia, Florida and Minnesota. We still have our first customer! • Our highly trained staff works in an efficient manner in order to achieve maximum productivity and keep program costs affordable. We have a detailed system and process that each of our field inspectors follow in order to meet productivity and quality assurance goals. • Our municipal inspection team is committed to providing outstanding customer service to the water users in each of the communities we serve. We teach and train customer service skills in addition to the technical skills since our team members act as representatives of the community that we service. • Our municipal inspection team has attended training classes and received certification from the following recognized Cross Connection Control Programs: UF TREEO, UW-Madison, USC – Foundation for Cross Connection Control and Hydraulic Research, American Backflow Prevention Association (ABPA), and American Society for Sanitary Engineering (ASSE). We invest heavily in internal and external training with our team members to ensure that each Field Service and Administrative team member has the skills and abilities to meet the needs of our clients. • Our administrative staff can answer most technical calls related to the cross-connection control program and have attended basic cross-connection control training classes. • HydroCorp staff and company are active members in many water industry associations including: o American Water Works Association (AWWA) | AWWA – Wisconsin Chapter o National Rural Water Association (NRWA) | Wisconsin Rural Water Association o American Public Works Association (APWA) • HydroCorp is not a Plumbing Company and does not utilize existing staff to perform backflow prevention assembly testing, repair or plumbing related services.
Company Overview. Backpack Exchange operates entities around the world to provide its Services to customers. You acknowledge and agree that the Specified Services shall be provided to Users in the Applicable Jurisdictions by the applicable Service Provider, in each case as set forth in Schedule A. In such case, the Specified Services shall be provided to you by the applicable Service Provider on and subject to this Agreement, with references in these general terms to Backpack Exchange being read as references to the Service Provider specified in Schedule A, unless the context provides otherwise, and under no circumstances shall any other person, including any affiliate of the Service Provider, be liable to you for the performance of any of the Service Provider’s obligations under this Agreement. All of the Service Providers are affiliates of Trek Labs Ltd, a company registered in the British Virgin Islands under the registration number 2120162 with its registered office at Xxxxxx House, Wickhams Cay II, PO Box 0000, Xxxx Xxxx, Xxxxxxx, XX0000, Xxxxxxx Xxxxxx Islands.
Company Overview. TerreStar Networks Inc. is a Reston, Virginia-based provider of advanced mobile communications services for the North American market. TerreStar plans to launch an innovative communications system to provide mobile coverage throughout the US and Canada using several classes of devices from a typical handset to vehicle mounted terminals. This seamless, ubiquitous network, based on integrated satellite/ground-based technology, will allow service in even the most hard-to-reach areas, and will finally allow for the interoperable, survivable and critical communications infrastructure that our nation’s first responders need. The TerreStar hybrid network will provide advanced IMS based 3.5/4G communication services for government, enterprise and personal customers. More information is available at xxxx://xxx.xxxxxxxxx.xxx/
Company Overview. Humacyte is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues with the goal of improving the lives of patients and transforming the practice of medicine. We believe our technology has the potential to overcome limitations in existing standards of care and address the lack of significant innovation in products that support tissue repair, reconstruction and replacement. We are leveraging our novel, scalable technology platform to develop proprietary, bioengineered, acellular human tissues for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. Our lead product candidate is being developed to address critical gaps in existing treatment options for acute vascular injuries in the extremities due to trauma in patient populations that cannot be adequately treated with either autologous vein or synthetic graft. On August 26, 2021 (the “Closing Date”), Humacyte, Inc. (“Legacy Humacyte”) and Alpha Healthcare Acquisition Corp. (“AHAC”) consummated a business combination pursuant to that certain Business Combination Agreement, dated as of February 17, 2021 (the “Business Combination Agreement”), by and among Legacy Humacyte, AHAC and Hunter Merger Sub (“Merger Sub”), a Delaware corporation and wholly owned subsidiary of AHAC. As contemplated by the Business Combination Agreement, Merger Sub merged with and into Legacy Humacyte, with Legacy Humacyte continuing as the surviving corporation and as a wholly owned subsidiary of AHAC (the “Business Combination”). On the Closing Date, AHAC changed its name to Humacyte, Inc. and Legacy Humacyte changed its name to Humacyte Global, Inc. AHAC was incorporated in Delaware on July 1, 2020. Additional information about us and our subsidiaries is included in documents incorporated by reference in this prospectus. See “Where You Can Find More Information” and “Incorporation by Reference.” Corporate Information Our common stock is traded on Nasdaq under the symbol “HUMA.” The mailing address of our principal executive office is 0000 Xxxx Xxxxx Xxxxxxxx Xxxxxxx 00, Xxxxxx, Xxxxx Xxxxxxxx 00000, and our telephone number is (000) 000-0000. Our website address is xxxx://xxx.xxxxxxxx.xxx. The information contained in, or that can be accessed through, our website is not part of this prospectus. We make available free of charge on our website our annual, quarterly and current reports, including amendments to such r...
Company Overview. About Netsync Network Solutions Founded in 2002, Netsync is a minority-owned business (MBE), women-owned small business (WOSB), and Texas Historically Underutilized Business (HUB) value-added reseller (VAR), specializing in technology solutions. We originated as a team of select senior technical consultants and built our business primarily through relationships and referrals, a true testament to the quality technology services Netsync provides. An end-to-end IT solutions consulting company, Netsync is based in Houston, TX, with offices across the US. Netsync uses a true business consultative approach to determine clients’ requirements and architects innovative and synergistic IT solutions to meet clients’ needs. Our highly skilled and seasoned engineering team is available 24 hours a day, 7 days a week, 365 days a year. Enterprise Networking Collaboration Service Provider Managed Services Security Data Center Cloud Optical/WAN Professional Services Client Experience Internet of Things Netsync helps public and private organizations implement complex IT strategies build on advanced technology solutions to achieve desired business outcomes. Our team of solution experts brings tangible business value through our progressive Design, Build, Deliver, and Manage services methodology. Netsync ensures each part of our clients’ infrastructure is architected, implemented, and supported to provide the best business value from their infrastructure.
Company Overview. We are a clinical-stage biotechnology company discovering and developing breakthrough treatments in immune-mediated and oncologic disorders. We believe therapies that inhibit multiple drivers of disease by targeting fundamental upstream control processes within the cell have the potential for profound therapeutic benefit in a number of difficult-to-treat diseases. To that end, we are advancing two drug development programs that harness different master regulators of cellular function: the first targets the immunoproteasome which is responsible for protein degradation in cells of the immune system and drives many key aspects of immune cell function, and the second targets the Sec61 translocon, which is located on the endoplasmic reticulum and represents the beginning of the protein secretion pathway. Targeting these fundamental regulators of cellular function offers an attractive approach to treating many diseases. Our lead product candidate, KZR-616, is a first-in-class selective immunoproteasome inhibitor that has completed Phase 1a testing in healthy volunteers and a Phase 1b trial in patients with systemic lupus erythematosus, or SLE. We are now leveraging its broad therapeutic potential in two Phase 2 clinical trials, MISSION and PRESIDIO, treating patients with severe autoimmune diseases characterized by high levels of unmet need. The Phase 2 portion of our MISSION clinical trial is evaluating KZR-616 in patients with lupus nephritis, or LN. The PRESIDIO Phase 2 clinical trial is evaluating KZR-616 in dermatomyositis, or DM, and polymyositis, or PM, indications for which we have been granted orphan drug designation, or ODD, by the U.S. Food and Drug Administration, or FDA. Based on Phase 1 clinical data generated to date with KZR-616, as well as preclinical data with selective immunoproteasome inhibitors, we believe that KZR-616 has the potential to address multiple chronic immune-mediated disorders. We believe that the immunoproteasome is a validated target for the treatment of a wide variety of immune-mediated disorders given its ability to regulate multiple drivers of the inflammatory disease process. Many inflammatory disorders are currently treated one cytokine or cell type at a time, but the immunoproteasome affects a broad spectrum of immune regulators. The compelling published activity seen with non-selective proteasome inhibitors administered to patients with severe autoimmune diseases provides proof of principle that inhibiting the immunopro...
Company Overview. Advanced Database Systems with our “theFMStudio” initiative, is an Australian professional services company with some of the most talented business analysts and FileMaker software engineers in the country. As a consequence, we are able to provide powerful FileMaker business solutions, ongoing support and maintenance and some very unique services. We’ve been in business in Australia since 1995 registering with ASIC in 1998. We are a highly focused team of 8 core members and introduce specific technology experts where appropriate. We have a sound track record of satisfied clients from within the corporate sector, federal and state government organisations and the small business community. Our clients often comment that while we deliver a highly professional service, we go about it in a refreshingly down-to-earth way. That's very much our style. ADS is currently engaged in the process of gaining ISO 9002 standards accreditation and has accreditation as a Federal Government endorsed supplier. Demonstrable results are achieved through understanding our clients and their businesses, listening to and interpreting their requirements, then translating those needs into rapidly deployed solutions or changes as requested. We do this by having a dynamic approach to achieving results. By engaging some of the best people in their fields, we cover every aspect of the development and delivery life-cycles: from initial investigation, business analysis and requirements gathering through to solution design, building & testing, deployment & final implementation. We believe that what we do and how we do it, are equally important. We have business people with a passion for helping others, and technical people intent on delivering to specification. Together we hope to develop a strong and enduring relationship.
Company Overview. Jagsonpal Pharmaceuticals Limited (“the Company”) is a domestic public company headquartered in Delhi, India. It is incorporated under the Companies Act, 1956 and its shares are listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and APIs. The Company has operations in India and caters to both domestic and international markets.
Company Overview. We are a global healthcare leader for developing and producing stabilized hypochlorous acid, or HOCl, products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. Our products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of HOCl show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Our stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. We also manufacture disinfectants that are distributed outside of the U.S. and in certain countries we have received regulatory clearance to state the disinfectant kills the coronavirus causing the COVID-19 pandemic. We sell our products either directly or via partners in 54 countries worldwide. The Offering Common stock offered by us Shares of our common stock having an aggregate offering price of up to $3,000,000.
Company Overview. Oncor, an indirect wholly-owned subsidiary of EFH, is a regulated electricity transmission and distribution company principally engaged in providing delivery services to the home for retail electric providers (“REPs”) that sell power in the North-central, Eastern and Western parts of Texas. Oncor also provides transmission services to other electricity distribution companies, cooperatives and municipalities; transmission grid connections to merchant power plants; and interconnections to other transmission grids in Texas. Oncor provides the essential service of delivering electricity safely, reliably and economically to end-use consumers through its transmission and distribution systems. For the twelve months ended June 30, 2007, Oncor generated total operating revenues of $2,478 million and Adjusted EBITDA of $1,129 million. As an electric transmission and distribution public utility in Texas, Oncor is regulated by the Public Utility Commission of Texas (“PUCT”). Oncor is the sixth largest transmission and distribution company in the U.S. and operates the largest distribution and transmission system in Texas, providing power to more than 3 million electricity delivery points, over more than 100,000 miles of distribution lines and 14,300 miles of transmission lines. At December 31, 2006, Oncor had approximately 3,400 full-time employees. Oncor operates within the Electric Reliability Council of Texas (“ERCOT”) region. ERCOT is the regional reliability coordinating organization for member electricity systems in Texas and the Independent System Operator of the interconnected transmission system of those systems. ERCOT is responsible for ensuring reliability, adequacy and security of the electric systems as well as nondiscriminatory access to transmission service by all wholesale market participants in the ERCOT region. ERCOT consists of approximately 150 members, including electric cooperatives, municipal power agencies, investor-owned independent generators, independent power marketers, electric transmission and distribution utilities and independent REPs. Oncor service territory and comparable infrastructure base Source: Energy Velocity, Company filings Electricity transmission Oncor’s electric transmission business is responsible for the safe and reliable operations of its transmission network and substations. These responsibilities consist of the construction and maintenance of transmission facilities and substations and the monitoring, controlling and di...
